Company / Shareholders' Equity
GeneDx Holdings Corp. Shareholders' Equity History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$308.2M
FY2025
5-year range
$228.0M / $388.1M
FY2021-FY2025
Trend
+25.7%
vs FY2024
Sector context
#131 of 166
Health Care
What the data says
GeneDx Holdings Corp.'s shareholders' equity of $308M is lower than 79% of companies in the Health Care sector (FY2025). Shareholders' Equity has fluctuated over the past 7 years, ranging from -$330M in FY2020 to $388M in FY2021.
Based on SEC 10-K filings.
$308M in FY2025 with a 3-year CAGR of +6.7%.
Improved from $228M to $308M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +6.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 21% in Health CareTop 79% of 166This company $308.2M Sector average $5.3B
▼
-94.1% below sector average
Key checks
Key Insights
- 3-year CAGR of +6.7%, indicating consistent growth.
- In FY2025, shareholders' equity increased 25.7% year-over-year.
- Ranks #131 out of 166 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- Negative profit margin: -17.1%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $308.2M | +25.7% |
| FY2024 | $245.2M | +7.6% |
| FY2023 | $228.0M | -10.1% |
| FY2022 | $253.7M | -34.6% |
| FY2021 | $388.1M | +217.6% |
| FY2020 | -$330.1M | -272.1% |
| FY2019 | -$88.7M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026